CNP
- Category
- Cardiovascular
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A natural vasodilating peptide marketed for cardiovascular and anti-aging support, though its strongest evidence is a long-acting analog's pediatric growth benefit for achondroplasia, not adult use. That effect is solid. Small human infusion experiments demonstrate vascular effects, but clinical cardiovascular benefit remains unproven. Main risks are injection-site reactions and transient blood-pressure drops. The pediatric analog is FDA-approved; native CNP is not, and unregulated products sold online carry no quality assurance.
Read Full recordStudied uses & evidence
Studied uses(6)
Increased annualized growth velocity by ~1.57 cm/year in children with achondroplasia
HighConfirmed in a randomized, placebo-controlled phase 3 trial of 121 children over 52 weeks.
Sustained growth improvement over 7 years of treatment in extension studies
MediumOpen-label extension studies show sustained growth benefit through 7 years, without a randomized comparator.
Improved body proportions (upper-to-lower segment ratio) with continued treatment
MediumExtension studies report improved body proportions versus historical controls, not a randomized comparison.
Evidence limits
- Evidence Level
- Strong Evidence (FDA-Approved Drug)
Vosoritide (Voxzogo) is backed by Phase 2 and Phase 3 randomized controlled trials, long-term extension studies out to 7 years, and real-world confirmation from multiple countries. The Phase 3 trial (n=121) met its primary endpoint with a statistically significant increase in growth velocity. FDA approved November 2021; EMA approved August 2021. Additional regulatory approvals in Japan, Australia, and other countries.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNot recommended for children outside an approved pediatric indication (vosoritide is approved for children with achondroplasia).
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions
HighTransient hypotension (temporary blood pressure drop)
ModerateVomiting and gastrointestinal symptoms
LowSerious adverse events (rare)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.